1. Home
  2. DLNG vs HUMA Comparison

DLNG vs HUMA Comparison

Compare DLNG & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dynagas LNG Partners LP

DLNG

Dynagas LNG Partners LP

HOLD

Current Price

$3.85

Market Cap

142.3M

ML Signal

HOLD

Logo Humacyte Inc.

HUMA

Humacyte Inc.

HOLD

Current Price

$1.08

Market Cap

155.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DLNG
HUMA
Founded
2013
2004
Country
Greece
United States
Employees
N/A
184
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
142.3M
155.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
DLNG
HUMA
Price
$3.85
$1.08
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$6.19
AVG Volume (30 Days)
63.9K
4.4M
Earning Date
05-26-2026
05-15-2026
Dividend Yield
5.18%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$444.16
Revenue Next Year
$1.10
$248.39
P/E Ratio
$3.04
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.40
$0.55
52 Week High
$4.45
$2.93

Technical Indicators

Market Signals
Indicator
DLNG
HUMA
Relative Strength Index (RSI) 41.25 69.71
Support Level $3.73 $0.92
Resistance Level $4.25 $1.27
Average True Range (ATR) 0.11 0.08
MACD -0.01 0.04
Stochastic Oscillator 15.15 95.41

Price Performance

Historical Comparison
DLNG
HUMA

About DLNG Dynagas LNG Partners LP

Dynagas LNG Partners LP is a limited partnership company focused on owning and operating high specification and versatile LNG carriers that are employed on multi-year contracts with international energy companies, providing the benefits of stable cash flows and high utilization rates. The company defines charters of two years or more as multi-year charters. Its current LNG Carrier fleet is optimized for trading flexibility. In addition to conventional trade, part of LNG Carrier fleet is assigned with Ice Class 1A FS notation and is winterized, which enables trade in subzero and ice bound conditions.

About HUMA Humacyte Inc.

Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.

Share on Social Networks: